STOCK TITAN
  1. Home
  2. News
  3. CMOPF

COSMO Pharmaceuticals N.V. - CMOPF STOCK NEWS

Welcome to our dedicated news page for COSMO Pharmaceuticals N.V. (Ticker: CMOPF), a resource for investors and traders seeking the latest updates and insights on COSMO Pharmaceuticals N.V..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect COSMO Pharmaceuticals N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of COSMO Pharmaceuticals N.V.'s position in the market.

News
Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care
Rhea-AI Summary
Cosmo Pharmaceuticals N.V. announces the launch of ColonPRO™ software, enhancing the GI Genius™ intelligent endoscopy system with improved AI-driven polyp detection and procedural highlights. Medtronic plc presents at the Genius Summit 2024, highlighting a new strategic collaboration with Cosmo and Modernizing Medicine® to enhance patient care. The GI Genius™ system has the potential to impact 2.7 million patients annually, with a 9% reduction in false positives due to the new software. The collaboration aims to streamline workflows, leverage augmented decision-making, and elevate the standard of care in endoscopic procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
News
Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per Share
Rhea-AI Summary
Cosmo Pharmaceuticals N.V. announced strong financial results for 2023, including revenue growth and key developments in GI Genius and Winlevi. The company's agreement with Medtronic and FDA approval of GI Genius's new operating system have bolstered its financial position. Cosmo's growth drivers continue to perform well, with Winlevi maintaining its position as the top prescribed acne product in the U.S. The company's development pipeline shows promise with ongoing trials for Breezula and other innovative treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
dividends earnings
-
News
Cosmo Pharmaceuticals Announces Approval of Winlevi(R) in Australia
Rhea-AI Summary
Cosmo Pharmaceuticals N.V. announced that its partner Sun Pharmaceutical Industries has received regulatory approval for Winlevi in Australia. Winlevi is a topical treatment for acne vulgaris in patients 12 years and older, set to launch in June 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Invitation to Cosmo's Investor Day and Full-Year 2023 Webcast - Zurich, 20 March 2024
Rhea-AI Summary
Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) announced the publication of its Full-Year 2023 results on March 20, 2024. The company invites investors, financial analysts, and journalists to a live video webcast presentation to discuss the financial and operating results. The webcast will be followed by an Investor Day in Zurich on the same day, including presentations from the company's management discussing its latest developments, commercial strategy, and key business highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care
Rhea-AI Summary
Cosmo Pharmaceuticals (COPN) and Medtronic plc (MDT) have expanded their partnership to revolutionize endoscopy with cutting-edge AI technology. The collaboration aims to improve patient outcomes and diagnostic tools through AI Access™ and the GI Genius module, increasing Medtronic's AI potential in healthcare. The agreement includes a $100 million upfront payment and potential milestone payments of $100 million expected to be reached by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
AI
-
News
Invitation to Cosmo's GI Genius™ Q&A session for investors, analysts and journalist
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Cosmo announces FDA approval of GI Genius™ intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
fda approval
-
News
Cosmo Full-Year Report 2020: Cosmo returns to operating profit
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Invitation to Cosmo's 2020 results / 2021 outlook presentation conference call on 26 March 2021
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock CMOPF logo
COSMO Pharmaceuticals N.V.

OTC:CMOPF

CMOPF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CMOPF Stock Data

1.22B
8.49M
47.15%
9.87%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Ireland
Sir John Rogersons Quay